N/A N=20 Randomized Quadruple-blind Treatment

Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet

Ischemia

Bottom Line

View on ClinicalTrials.gov: NCT01072669 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2013

Primary outcome: Primary: Digital Micro-vascular Flow — .11; .18; -.01; -.06 perfusion unit

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: ambrisentan (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Soumya Chatterjee
Primary completion: Dec 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Digital Micro-vascular Flow	.11; .18; -.01; -.06	—

Summary

The purpose of this study is to investigate the effectiveness of a drug called ambrisentan, approved by the FDA for use in pulmonary hypertension (a condition where there is increased pressure in the right side of the heart) in scleroderma patients, to see if this medicine may be beneficial in relieving and/or preventing Raynaud's flares in you and other patients like you. This medicine may have some short-term and long-term benefits in persons with scleroderma

Eligibility Criteria

Inclusion Criteria

Subjects should have limited scleroderma with disease duration 7 years

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01072669). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.